Skip to main content
Janssen seeks FDA approval of prostate cancer drug

A new-drug application was filed with the FDA by Janssen Biotech for apalutamide, which is being developed as a treatment for men with nonmetastatic castration-resistant prostate cancer. A late-stage study showed a statistically significantly extension of metastasis-free survival in patients who use apalutamide versus placebo.

Full Story: